Clinical trial NCT02388971: Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease
Official title: A Randomized, Double-Blind Placebo- Controlled Phase 2a Study to Assess the Effect of CCR2 Antagonism by MLN1202 on Atherosclerotic Inflammation in Subjects With Stable Atherosclerotic Cardiovascular Disease Using FDG PET/CT Imaging
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Atherosclerotic Cardiovascular Disease
Keywords: Drug therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2015-03-17
Enrollment: 0
Sex: ALL
Minimum age (years): 35
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of MLN1202 on arterial inflammation in participants with stable atherosclerotic cardiovascular disease (CVD) who are receiving standard-of-care (SOC) therapy.

Detailed description: The drug being tested in this study is called MLN1202. MLN1202 is being tested to treat people who have stable atherosclerotic cardiovascular disease (CVD). This study will look at changes in arterial inflammation in people who take MLN1202 in addition to standard-of-care (SOC) therapy.

The study will enroll approximately 108 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

* MLN1202 Dose A intravenously (IV)
* Placebo (dummy inactive solution) - this is a solution that looks like the study drug but has no active ingredient

All participants will receive IV administration of MLN1202 or placebo on Day 1, Day 29, and Day 57 of this study.

This multi-centre trial will be conducted in the United States. The overall time to participate in this study is 19 weeks. Participants will make 7 visits to the clinic, and will be contacted by telephone approximately 35 days after last dose of study drug for a follow-up assessment.

Eligibility criteria: Inclusion Criteria:

1. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form (including consent for pharmacogenomics \[PGx\] collection) and any required privacy authorization prior to the initiation of any study procedures.
2. Is male or female and aged 35 to 80 years, inclusive at Screening.
3. Has documented atherosclerotic vascular disease (eg, coronary artery disease (CAD), peripheral arterial disease, aortic atherosclerosis or abdominal aortic aneurysm (\<5 cm), carotid disease, or cerebrovascular disease) and has been clinically stable for at least 3 months prior to Screening. Documentation sufficient to demonstrate presence of atherosclerotic vascular disease will include one or more of the following:

   * i. History of myocardial infarction.
   * ii. History of stroke.
   * iii. Framingham score indicating \>20% 10-year risk in an individual who is age \>55.
   * iv. Documentation of atherosclerotic disease by objective diagnostic testing.
4. Are willing to undergo 2, 2-deoxy-2-\[\^18F\]-fluoro-D-g1ucose positron emission tomography (FDG PET)/CT scans, have a body weight compatible with their imaging center's PET/CT scanner table limits and be able to tolerate the imaging procedure.
5. Are statin naïve or are taking a stable statin dose AND, if taking a statin, are not on a high dose of a high-potency statin. A high-dose of high potency statin is defined as atorvastatin ≥40 mg/day or rosuvastatin ≥20 mg/day. Furthermore, statin dose must be stable for at least 6 weeks prior to Screening FDG PET /CT scan and must not be changed during the remainder of the study.

Exclusion Criteria:

1. Has a history or clinical manifestations of:

   * a) Type 1 diabetes mellitus.
   * b) Significant heart failure (eg, New York Heart Association class III or IV).
   * c) Active or chronic liver disease.
   * d) Any chronic systemic inflammatory condition requiring ongoing therapy with anti-inflammatory drugs.
   * e) Any history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Day 1 of this study.
   * f) Any infection requiring antibiotic therapy within 6 weeks prior to Screening FDG PET/CT.
   * g) Any acute infection within 2 weeks of Screening FDG PET/CT scan.
   * h) Impaired renal function (estimated creatinine clearance \<60 ml/min as calculated by the Cockcroft Gault formula). Re-testing may be allowed on a case by case basis.
2. Requires ongoing therapy with any systemic anti-inflammatory drugs (except nonsteroidal anti-inflammatory drug \[NSAIDs\]), including systemic anti-inflammatory steroids, methotrexate, colchicine, anti-inflammatory biologics, or any other compound that in the opinion of the investigator has a substantial anti-inflammatory effect.
3. Has received treatment with systemic immunosuppressant or systemic anti- inflammatory medications within 6 weeks prior to Screening FDG PET/CT scan.
4. Has a history of hypersensitivity or allergies to any component of the study medication or history of hypersensitivity to monoclonal antibodies.
5. Has any significant medical condition(s) which, in the investigator's opinion, may interfere with the participant's optimal participation in the study.
6. Has poorly controlled blood glucose, defined for the purposes of this study as glycosylated hemoglobin (HbA1c) ≥7.75% at Screening.
7. Screening FDG PET/CT scan has inadequate vascular uptake (target to background ratio \[TBR\] \<1.6) in all of the index vessels (ascending aorta, left carotid, right carotid) as assessed by the imaging core laboratory.

Primary outcomes:
measure: The change in arterial FDG uptake from MLN1202 treatment relative to placebo, comparing pretreatment and 3 month post-treatment time points
timeFrame: Baseline and 3 month post-treatment
Secondary outcomes:
measure: The change in arterial FDG uptake from MLN1202 treatment relative to placebo, comparing pretreatment and 3 month post-treatment time points in subjects identified using a dominant model of the snip in the MCP-1 polymorphisms [MCP-1 -2518 (rs1024611)].
timeFrame: Baseline and 3 month post-treatment
measure: Change from Baseline in Mean Carotid Vessel MDS TBR
timeFrame: Baseline and Day 82
measure: Change from Baseline in Mean Active Segment TBR
timeFrame: Baseline and Day 82
measure: Change from Baseline in Mean Index Vessel TBR
timeFrame: Baseline and Day 82
measure: Change from Baseline in Mean Carotid Vessel TBR
timeFrame: Baseline and Day 82
Other outcomes:
Locations:
Study officials:
affiliation: Takeda
name: Medical Director Clinical Science
role: STUDY_DIRECTOR
References: